View Older Stories View More Recent Stories

Oct 19, 2025 02:30AM Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
Oct 13, 2025 08:32AM Gilead to present Trodelvy breast cancer data at ESMO 2025
Oct 13, 2025 08:30AM Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
Oct 9, 2025 04:05PM Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Sep 25, 2025 08:00AM Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Sep 4, 2025 02:15PM Gilead partners with PEPFAR to deliver HIV prevention drug to 2 million people
Sep 4, 2025 02:15PM Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Sep 3, 2025 11:32AM Gilead Sciences breaks ground on new manufacturing facility in Foster City
Sep 3, 2025 11:30AM Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
Aug 26, 2025 03:00AM European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Aug 20, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Jul 25, 2025 05:58AM Gilead receives positive EU opinion for twice-yearly HIV prevention drug
Jul 25, 2025 03:00AM Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
Jul 24, 2025 04:05PM Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Jul 14, 2025 09:31AM Gilead presents data on twice-yearly HIV prevention drug at IAS 2025
Jul 14, 2025 09:30AM Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
Jul 9, 2025 08:00AM Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Jun 25, 2025 07:02AM Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 25, 2025 07:00AM Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 18, 2025 02:50PM Gilead Sciences (GILD): Yeztugo Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Jun 18, 2025 02:49PM Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
May 31, 2025 08:00AM Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
May 23, 2025 08:32AM Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study
May 23, 2025 08:30AM ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast C
May 15, 2025 04:15PM Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th
May 7, 2025 02:30AM Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
May 7, 2025 02:15AM Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
Apr 29, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 29, 2025 08:31AM Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Apr 29, 2025 08:30AM Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
Apr 21, 2025 08:31AM Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC
Apr 21, 2025 08:30AM Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Ne
Apr 10, 2025 04:05PM Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
Mar 12, 2025 08:31AM Gilead Sciences (GILD) Presents New HIV Treatment and Cure Research Data
Mar 12, 2025 08:30AM Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Mar 11, 2025 01:38PM Gilead Sciences (GILD) Presents First Clinical Data for Investigational Once-Yearly Lenacapavir for HIV Prevention
Mar 11, 2025 01:37PM First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Feb 24, 2025 08:30AM European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
Feb 20, 2025 04:30PM Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Feb 19, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 18, 2025 08:30AM Gilead Sciences (GILD): U.S. FDA Accepts New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Feb 18, 2025 08:30AM U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Feb 11, 2025 04:05PM Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
Jan 28, 2025 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Jan 22, 2025 08:30AM Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
Jan 11, 2025 11:00AM Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Dec 20, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 17, 2024 08:33AM Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy
Dec 17, 2024 08:30AM U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024 07:02AM Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
View More Recent Stories View Older Stories